¼ÓÈëVIP ÉÏ´«¿¼²©×ÊÁÏ ÄúµÄÁ÷Á¿ Ôö¼ÓÁ÷Á¿ ¿¼²©±¨°à ÿÈÕÇ©µ½
   
Ö÷Ìâ : µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ
¼¶±ð: ³õ¼¶²©ÓÑ
ÏÔʾÓû§ÐÅÏ¢ 
Â¥Ö÷  ·¢±íÓÚ: 2007-04-19   

µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ

µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ ѧ¿Æרҵ£º F%^)oQT+c  
4g^X e-  
´«È¾²¡Ñ§ ¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ &_ W~d0  
#f-pkeaeq  
Ò». Ãû´Ê½âÊÍ(ÿÌâ4·Ö,¹²32·Ö) 5tQZf'pHfd  
RSK5 }2  
1. ICAM-1 XAw0Nn   
%+0V0.  
2. interleukin 12(IL-12) B`?}jJa9*  
>dYN@cB$}  
3. tumor infiltrating lymphocyte q3}WO] TBj  
cPbAR'  
4. TCR/CD3 complex  G%5ZG$as  
> xie+ ^  
5. hematopoietin receptor family lNba[;_  
^SC2k LI  
6. individual idiotype(IdI) =u 3YRqz  
L. DD  
7. integrin 3:"w"0[K3  
Z,1b$:+  
8. colony-stimulatory factor (CSF) U\GuCw  
+sFpIiJg  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© (Qf. S{;  
A5?q&VS}p  
1. ÃâÒßÇòµ°°×ÖØÁ´µÄ»ùÒòÈçºÎ½øÐÐÀà±ðת»»(class switching )? ><i: P*ht  
7^W(es  
2. ¼òÊöɱÉËÐÔTϸ°û(Tc)ɱÉ˲¡¶¾¸ÐȾ°Ðϸ°ûµÄ»úÀí¡£ gAr =fq-|  
ToX--w4  
3. ÉúÎïÓ¦´ðµ÷½Ú¼Á( biological response modifier,BRM)Ö÷ÒªÓÐÄļ¸Àà?¼òÒª½éÉÜÔÚ´«È¾ÐÔ¼²²¡·ÀÖÎÖеÄ×÷ÓᣠPWk\#dJN&  
C2C 1 @=w  
4. ¼òÊö¿¹Ô­Ìá³Êϸ°û(APC)Ó븨ÖúÐÔTϸ°û(Th)Ï໥×÷ÓõĹØϵ¡£ 2Og<e|  
]\m >N]P]  
Èý. ÎÊ´ðÌâ(ÿÌâ18·Ö,¹²36·Ö) %&j \:X~A  
`!Yd$=*c_&  
1. ÊÔÊö¸ÉÈÅËصķÖÀ༰ÆäÉúÎïѧ×÷ÓÃÌص㡣Ö÷Òª¿ÉÒÔÖÎÁÆÄÄЩ´«È¾ÐÔ¼²²¡?¼òÊö¸ÉÈÅËؼì²âµÄ·½·¨ºÍÔ­Àí¡£ ,Q<mU4  
'Y0h w  
2. ºÎΪ»ùÒò¹¤³Ì¿¹Ìå?Ä¿Ç°¹úÄÚÍâÔÚ»ùÒò¹¤³Ì¿¹ÌåÑо¿ÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? µÚËľüÒ½´óѧһ¾Å¾ÅÈýÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ѧ¿Æרҵ: ´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© 1. CD4 2. T cell receptor(TCR) X^Fc^U8  
qs!A)H#  
3. immunoglobulin superfamily (IgSF) Vw]!Kb7tA  
xauMF~*  
4. selectin mgMa)yc!dp  
yw1-4*$c  
5. anti-idiotypic antibody (¦ÁId) 3,?LpdTS  
2Q5 -.2]  
6. major histocompatibility complex(MHC) gI!d*]{BP  
{krBAz&  
7. immunotolerance 9oYE  
?j&ZzK'#^  
8. biological reponse modifier(BRM) WK0:3q(P  
Z/czAr@4  
9. immune reponse gene (Ir gene) vi28u xc  
Fw:_O2  
10. reshaped antibody (or reconstituted antibody) ,0c]/Sd*p  
ST2:&xH(  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£©  aWPf3Q  
i+F*vTM2,  
1. ¼òÊö°×ϸ°û½éËØ6(IL-6)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¡£ '{-Ic?F<P  
cyo[HI?WM  
2. ϸ°û¶¾ÐÔTÁÜ°Íϸ°û(Tc»òCTL)Ó뿹ÌåÒÀÀµµÄϸ°û½éµ¼µÄϸ°û¶¾(ADCC)ɱÉË»úÀíÓкβ»Í¬? 33 ; '6/  
(%OZ `?`  
3. ¼òÊöµÚ¢ôÐÍ(³Ù·¢ÐÍ)±ä̬·´Ó¦µÄ·¢Éú»úÀí¡£ Zrp-Hv27,,  
UVXSW*$  
4. NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄ±íÃæ±ê¼Ç?NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄÉúÎïѧ»îÐÔ? W*%(J$E  
AOJ[/YpM  
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö) ¹©´«È¾²¡Ñ§×¨ÒµÊÔÌ⣺ Npi) R)  
_a f $0!  
1. »úÌåÓÐÄÄЩÃâÒßϸ°ûºÍÃâÒß·Ö×Ó²ÎÓ뿹²¡¶¾¸ÐȾ?ËüÃÇÊÇÈçºÎ·¢»Ó²¡¶¾ÃâÒß×÷ÓõÄ? uq ;yR[w"  
I,<?Kv  
2. Ä¿Ç°µ¥¿Ë¡¿¹ÌåÔÚ²¡¶¾Ñ§ÖÐÓÐÄÄЩÖ÷ÒªÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? ¡¡ R$+p4 @?S  
JEaTDV_  
¹©Ïû»¯ÄÚ¿ÆרҵÊÔÌ⣺ ;6~5FTmV  
=H3tkMoi2  
1. Ä¿Ç°ÌåÄÚºÍÌåÍâ¼ì²âÖ×Áö»¼ÕßÃâÒß¹¦Äܵķ½·¨Ö÷ÒªÓÐÄÄЩ?·Ö±ðÐðÊöÿÖÖ·½·¨µÄÔ­ÀíºÍ½á¹û²â¶¨? I)y F!E &  
H>W8F2VT  
2. Ä¿Ç°µ¥¿Ë¡¿¹ÌåÔÚÖ×ÁöѧÖÐÓÐÄÄЩÖ÷ÒªµÄÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? ¡¡ MB7*AA;  
5\= y9Z- x  
µÚËľüÒ½´óѧһ¾Å¾ÅËÄÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ѧ¿Æרҵ: p_(En4QSH  
rwVp}H G  
´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿: &q@brX<,=  
%<x! mE x  
ÃâÒßѧ Uqb]&2  
d,?Tq  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© BjagG/ sX  
;g? |y(xv  
1. CD8 /s~S\dG  
M2N8?Ycv3  
2. T cell receptor ¦Á and ¦Â chain (TCR¦Á¦Â ) WubV?NX;EF  
b,YNCb]H  
3. immunoglobulin fold(Ig fold) %T\hL\L?  
huS*1xl  
4. cadherin (Ca-dependent cell adhesion moleculers) )Z:D}r8[  
Ei):\,Nv  
5. idiotype-anti-idiotypic antibody immune network theory QxdC[t$Lp  
9aY8` B  
6. HLA class II antigen W.?/p~  
"GQ Q8rQ  
7. complementarity-determining region (CDR) qSB&Q0T  
* dw.Ug  
8. perforin(or pore-forming protein ,PFP) [)1vKaC  
{\(MMTQ  
9. high affinity IL-2 receptor Y55u -9|N  
QJRnpN/  
10. artificial active immunization T"W<l4i-  
ro\  oL  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© p>;@]!YWQ  
MCmb/.&wu  
1. ¼òÊö°×ϸ°û½éËØ2(IL-2)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¼°ÆäÔÚÁÙ´²ÖÎÁÆÖеÄÓ¦Óᣠrobg1  
qrYbc~jI7  
2. Çë±È½ÏµÚ¢ñÐÍ(ËÙ·¢ÐÍ)³¬Ãô·´Ó¦ÓëµÚ¢ôÐÍ(³Ù·¢ÐÍ)³¬Ãô·´Ó¦µÄ·¢²¡Ìص㡣 _E`+0;O  
YE{ [f@i0  
3. ÊÔÊö·ÖÃÚÐÍIgA(secretory IgA)µÄ½á¹¹ÌصãºÍºÏ³É·ÖÃÚ¹ý³Ì¡£ z6C(?R  
;na%*G`  
4. ÊԱȽÏT¡¢BÁÜ°Íϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(Èç±íÃ濹ԭ¡¢±íÃæÊÜÌåµÈ)µÄÒìͬµã¡£ > 0MP[  
31a,i2Q4  
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö¡£Çë×¢Ò⣺ÿλ¿¼ÉúÖ»ÄÜ´Ó1¡¢2ÌâÖÐÑ¡Ò»Ìâ,3¡¢4ÌâÖÐÑ¡Ò»Ìâ,¹²´ðÁ½Ìâ,¶à´ðÕß²»¼Æ·Ö¡£) 1. Ä¿Ç°¼ì²âϸ°ûÒò×ÓÖ÷ÒªÓÐÉúÎïѧ»îÐÔ¼ì²â·¨ºÍÃâÒßѧ¼ì²â·¨,Çë¾ÙÀý·Ö±ðÐðÊöÁ½ÖÖ·½·¨µÄʵÑéÔ­Àí¡£ d"9tP& Q  
&Mk!qE<:N  
2. ΪÁ˱ÜÃâIgG¿¹ÌåFc¶Î·ÇÌØÒìÐÔ×÷ÓÃ,³£Ó¦ÓÃθµ°°×øˮ½âµÄF(ab¡¯)2¶Î,ÊÔÎÊÈçºÎÓ¦ÓÃSDS-PAGE·½·¨¶ÔF(ab¡¯)2½øÐмø¶¨? M`H#Qo5/  
heCM+ =#~  
3. ÊÔÊö¿¹Ö×Áö»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ bTc >-e,  
:rVR{,pL  
4. ÊÔÊö¿¹²¡¶¾»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ ¡¡ # dWz,e3   
sv% X8   
µÚËľüÒ½´óѧһ¾Å¾ÅÎåÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ v'@gUgC  
{r&mNbz  
ѧ¿Æרҵ£ºÃâÒßѧ¡¢´«È¾²¡Ñ§¡¢Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿£ºÃâÒßѧ Swhz\/u9  
$72eHdy/yl  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© 6DHK&<=D8  
DWt|lO  
1. immunoglobulin gene rearrangement rUb{iU;~m  
0+FPAqX  
2. the common chain of cytokine receptor (or a cytokine receptor subunit shared by some cytokine receptors) [<R haZz  
]!B0 = XP  
3. flow cytometry(FCM) 4^L;]v,|7  
Y\]ZIvTSb  
4. carrier effect ~v;I>ij  
.5 . (S^u  
5. positive selection of T lymphocytes in thymus ,TQec:B  
+#FqC/`l  
6. mouse TH1(Th1) and TH2(Th2) subsets %} `` :  
e"S?qpJK  
7. perforin (pore-forming protein ,PFP) E)_n?>Ar  
zr.\7\v  
8. ADCC(antibody-dependent cell-mediated cytotoxicity) Fc5.?X-  
Tz @=N]D  
9. SH-2(src-homology region 2) @|b-X? `  
^1S{::  
10. Ab2¦Â (internal image) TJ"-cWpO1  
lmeTW0U@9(  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© x6UXd~ L e  
/+Z*)q+SbT  
1. ½üÄêÀ´ÔÚÈËÀà°×ϸ°û·Ö»¯¿¹Ô­(CD)Ñо¿ÁìÓòÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? xb,d,(^]R  
%~!4DXrMk  
2. ²ÎÓë»î»¯Tϸ°ûÓë»î»¯Bϸ°ûÏ໥×÷ÓõķÖ×ÓÖ÷ÒªÓÐÄÄЩ?¼òÊöÆä½á¹¹ºÍ¹¦ÄÜ? Ul}RT xJ  
kUd]8Ff!  
3. ÊÔÊöHLAÔÚÁÙ´²ÉϵÄÖ÷ÒªÓ¦Óᣠa{nR:zPE  
M=^d  
4. Àý¾ÙÈýÖÖ´ÓÈËÍâÖÜѪµ¥¸öºËϸ°û(PBMC)Öд¿»¯Tϸ°ûµÄ·½·¨,·Ö±ðÐðÊöÆäʵÑéÔ­ÀíºÍÖ÷Òª²Ù×÷²½Öè¡£ nI*.(+h  
(7Z+De?  
5. ÆÀ¼Ûºìϸ°ûÉú³ÉËØ(EPO)¡¢¸ÉÈÅËØ(IFN)ºÍ¼¯Âä´Ì¼¤Òò×Ó(CSF)ÔÚÁÙ´²Ä³Ð©¼²²¡µÄÓ¦Óᣠ2l<2srEK  
/$c87\  
Èý. Ñ¡ÔñÎÊ´ðÌâ(ÿÌâ10·Ö,¹²20·Ö¡£Çë°´±¨¿¼×¨Òµ´ðÌâ,Èç´ð·Ç±¾×¨ÒµÌâ»ò¶à´ðÌâ¾ùÊÓΪÎÞЧ¡£) : 21d  
<V&0 GAZ  
ÃâÒßѧרҵ£º ZNQ x;51  
b@Oq}^a&o  
1. ÊÔÊöϸ°ûÒò×ÓÊÜÌåÖÐ,Ig³¬¼Ò×å¡¢ÔìѪÒò×ÓÊÜÌ峬¼Ò×å¡¢Éñ¾­Éú³¤Òò×ÓÊÜÌ峬¼Ò×åÒÔ¼°Ç÷»¯Òò×ÓÊÜÌ峬¼Ò×åµÄÖ÷Òª½á¹¹Ìصã,ÿ¸ö³¬¼Ò×åÀý¾Ù³ö2¸ö³ÉÔ±¡£ 2aYBcPFQh#  
%(YQ)=w  
2. ÊԱȽÏÈËT¡¢BÁÜ°Íϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(±íÃæ±ê¼Ç)µÄÒìͬµã,ËüÃÇ·Ö±ð²ÎÓëÄÄЩÖ÷ÒªµÄÃâÒß¹¦ÄÜ? 6 VEB2F  
p!UR;xH I\  
´«È¾²¡Ñ§×¨Òµ£º j "qND=15  
nTy]sPn  
1. ÈËÀàÃâÒßȱÏݲ¡¶¾(HIV)¸ÐȾÈËÌåºó,ÃâÒß¹¦ÄÜ¿É·¢ÉúÄÄЩÖ÷ÒªµÄ±ä»¯?»úÀíÊÇʲô?ÈçºÎ½øÐÐÏàÓ¦µÄÃâÒßѧ¹¦Äܼì²â£¿ c{M ,K  
(/]'e}  
2. ÇëÆÀÊöÉö×ÛºÏÕ÷³öѪÈȲ¡¶¾(HFRSV)¸ÐȾºó»úÌåÃâÒßѧ±ä»¯µÄÓ벡ÀíËðÉ˵ĹØϵ¡£ Uy?jVPL  
#3&@FzD_P  
Ïû»¯×¨Òµ£º $[|(&8 +7  
T\l`Y-vu  
1.ÊÔÊöÓëÏû»¯ÏµÍ³ÓйصÄÖ×ÁöÏà¹Ø¿¹Ô­Ñо¿µÄ½øÕ¹¡£ ^ij0<*ca9  
h(|T.  
2.¼òÊöճĤÏà¹ØÁÜ°ÍÑù×éÖ¯(mucosal assiociated lymphoid tissue,MALT)µÄ×é³ÉºÍ¹¦ÄÜÌص㡣·ÖÃÚÐÍIgAÊÇÈçºÎ½øÐкϳɺͷÖÃÚµÄ? X-["{  
QEyL/#Q  
µÚËľüÒ½´óѧһ¾Å¾ÅÁùÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ÃâÒßѧÊÔÌâ ;(i6 X)  
@](vFb  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© :;{M0  
:&BPKqKp  
1. Fas(CD95)/FasL "Rj PTRe:  
 YSD G!  
2. common chain of cytokine receptor @| z _&E  
2 @#yQB1  
3 . TCR/CD3 complex V*?cMJ_G  
h@%Xy(/m'  
4. negaive selection of thymocytes +C SpL2@  
P $` 1}  
5. artificial active immune Dz}i-tw+  
JxVGzb`8  
6. anti-idiotypic @)Vpj\jM-C  
#UM,)bH  
7. IgSF alb3oipOB  
<6Q^o[L  
8. Integrin %-n) L  
3%POTAw%  
9. chemokine ~5HkDtI)  
L)'G_)Sl  
10. B7/CD28 7By7F:[b  
aT0~C.vT  
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²60·Ö£© un "I  
<9@n/  
1. ±È½ÏMHC¢ñºÍMHC¢òÀ࿹ԭ²ÎÓëµÄ¼Ó¹¤Ìá³Ê¿¹Ô­µÄ¹ý³Ì¡£ 3BM z{ny=  
opa/+V3E4  
2. ±È½ÏCTLºÍNKɱÉË°Ðϸ°ûʱʶ±ðºÍɱÉË»úÖƵÄÌص㡣 '{d _q6,%  
T~UDD 3  
3. ±È½ÏÃâÒßѧ¼ì²â·¨ºÍÉúÎïѧ»îÐÔ¼ì²â·¨¼ì²âϸ°ûÒò×ÓµÄÓÅȱµã¡£ 0+\725DJ  
S`-I -VS=L  
4. ·¢ÏÖÒ»ÖÖеİ×ϸ°û·Ö»¯¿¹Ô­»òÖ×ÁöÏà¹Ø¿¹Ô­,²¢ÖƱ¸Á˵¥¿Ë¡¿¹Ìå,ÊÔÉè¼ÆʵÑé·½°¸¿Ë¡´Ë»ùÒò¡£ hW*o;o7u  
+<E#_)}`D6  
5. Ñ¡ÔñÏÂÊöÖÐÒ»¸öרÌâ,ÐðÊöÎÒ¹úÔÚÕâÒ»Ñо¿ÁìÓòµÄÏÖ×´¼°ÃæÁÙµÄÌôÕ½1)Ö×ÁöÃâÒߣ»(2)»ùÒòÖÎÁÆ£»(3)CD¿¹Ô­¡£ >iT mILA  
S1=P-Ao  
µÚËľüÒ½´óѧһ¾Å¾ÅÆßÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÃâÒßѧÊÔÌâ fN2Sio:  
,M.C]6YMr  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£©  2s}S9  
R}oN8  
1. B7/CD28 @5Tl84@Q  
<K)]kf  
2. Th1 subset ;+75"=[YT  
u 7e$Mq  
3. seven predicated transmembrane domain receptor superfamily£¨STR superfamily£© CPZ{  
#Y= A#Yz,{  
4. antibody affinity maturation "kApGNB  
&N.pW=%,N  
5. AP-1 YKe&Ph.  
3,i j@P  
6. single chain variable fragment£¨ScFv£© NDRD PD  
[#KY.n  
7. NK cell receptor c|<F8 n  
. vHHw@  
8. Zinkernagel-Doherty phenomenon &r[f ;|o  
CDJ@Tdp  
9. Ig fold K+Him] b  
sm18u-  
10. CD40/CD40L 8R)K$J$Hm  
";.j[p:gi  
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²36·Ö£© [>NMuwtG  
|-JG _i  
1. ÊÔÊöÐØÏÙ΢»·¾³¶ÔÐØÏÙϸ°ûµÄÑ¡Ôñ×÷Óü°ÆäÓëTϸ°û¹¦ÄÜÐÔÑÇȺÐγɵĹØϵ¡£ 9swHa  
feX o"J  
2. ÊÔÊöÌåÒºÃâÒßÓ¦´ðµÄ¹æÂÉ£¬»ØÒä·´Ó¦ºÍ¿¹ÌåÀà±ðת»»µÄ»úÖÆÊÇʲô£¿ ]fb@>1 jp  
^S|qGu,G  
3. ÊԴӽṹºÍ¹¦ÄܵȽǶȣ¬²ûÊö°×ϸ°û·Ö»¯¿¹Ô­£¨CD£©¡¢Õ³¸½·Ö×Ó£¨integrin£©ºÍÃâÒßÇòµ°°×³¬¼Ò×壨IgSF£©ÈýÀà·Ö×ÓµÄÏ໥¹Øϵ¡£Ä¿Ç°ÔÚÕâÒ»ÁìÓòÖÐÖ÷ÒªÑо¿ÈȵãÊÇʲô£¿ F,vkk{Z>  
+VVn@=&?  
Èý. ÎÊ´ðÌ⣨24·Ö£¬µÚ1ÌâΪÃâÒßѧרҵ¿¼ÉúÊÔÌ⣬µÚ2ÌâΪѪҺ²¡Ñ§¿Æ¿¼ÉúÊÔÌ⣬µÚ3ÌâΪÏû»¯ÄÚ¿Æ¿¼ÉúÊÔÌ⣬ֻÔÊÐí´ð±¾×¨ÒµÊÔÌ⣩ J>R $K  
|}{gE=]  
1. ÊԱȽÏTCRºÍBCR½á¹¹¼°Æäʶ±ð¿¹Ô­¡¢ÁÜ°Íϸ°û»î»¯ÐźŵķÖ×Ó»úÀí¡££¨ÃâÒßѧרҵ£©¡£ 4lPO*:/  
+1#oVl !  
2. ÊÔÊö°×Ѫ²¡ÃâÒßѧ·ÖÐÍÀíÂۺͷ½·¨µÄÑо¿½øÕ¹¡££¨ÑªÒº²¡Ñ§×¨Òµ£©¡£ M? 8s y  
p+g=Z<?`  
3. ÊÔÊöÖ×ÁöÒßÃçµÄÑо¿½øÕ¹¡££¨Ïû»¯ÄÚ¿Æרҵ£©¡£ qBF|' .$^  
QE/kR!r  
Ò»¾Å¾Å°ËÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ £¨ÃâÒßѧרҵºÍרҵ»ù´¡£© 5H Cw%n9  
f5//?ek  
Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£© bB0/FiY7o  
:PV3J0pB~  
1.Co-stimulators (or co-stimulating molecules) 1E$\&*(  
In4VS:dD  
2.NK-kB wYe;xk`>  
M2V`|19Q  
3.Immunoglobulin superfamily OfrzmL<K  
H6Zo|n  
4.antigen-presenting cell (APC) ~NE`Ad.G  
/w?zO,!  
5.death domain !L +b{  
h>>~Bi  
6.CCR and CXCR ?6"U('y>n  
v~ x`a0  
7.Lectin (or mitogen) {|$kI`h,3-  
s5v}S'uO{  
8.Clusters of differentiation, CD) N[-$*F,:_  
d_:f-  
9.B7 family Dy5&-yk  
'_Q';T_n99  
10.Cytotoxic T lymphocyte, CTL) G_qt~U  
%<+Ku11  
11.IL-15 and IL-15 receptor (IL-15R) 16N |  
6Ik v}q_j  
12.MHC restriction P_H2[d&/>D  
@/N]_2@8;  
13.Affinity-chromatography >bI\pJ  
[OPF3W3z  
14.Cyctosprin A, CsA 'Sgz\ =K  
s(Wys^[g  
15.Antibody-dependent cell-mediated cytotoxicity, ADCC) |F\fdB}?S:  
i" +TKo-  
¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£© QxbG-B^)=  
./zzuKO8XK  
1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿 =/xx:D/  
Ll%}nti  
2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØϵ¡£ X%og}Cfi  
FWp ?l  
3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹Ô­µÄÌص㡣 eu]qgtg~U  
Z6 -  
Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£© z[vu- f9  
*q\>DE=7  
ÃâÒßѧרҵ£º mBB"e"o  
<e  S+3,  
1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£ A"qDc  
)p#L"r^)  
Ïû»¯ÄÚ¿Æ£º 2.Ö×Áö¿¹Ô­·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£ !?J- Y  
8$RiFD ,  
ѪҺ²¡Ñ§×¨Òµ£º 3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎΪÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔ­Òò£¨Ìõ¼þ£©ÊÇʲô£¿ e]dFNunFq0  
xh#pw2v7V  
Ò»¾Å¾ÅÄê¾Å²©Ê¿ÉúÈëѧ¿¼ÊÔÊÔÌâ (רҵ»ù´¡: ÃâÒßѧ) CbxWK#aMmB  
F|'u0JQ)$  
Ò».Ãû´Ê½âÊÍ(ÿÌâ5·Ö,¹²45·Ö) tnBCO%uG  
Q.3 :"dT  
1. ADCC(antibody dependent cell-mediated cytotoxicity) a3A3mBw  
zN)).a  
2. »·æß¾úËØ(cyclosporin) X(.[rC>  
c4Q9foE   
3. KIR(killer cell inhibitory receptor) WjSu4   
=\MAz[IDj  
4. HLDA(human leucocyte differentiation antigen) ^wwS`vPb  
z yp3 +|  
5. Interleukin 18(IL-18) < $Sl%DoS  
YdIZik F#  
6. ÕûºÏËØ(integrin) <u],R.S)  
Lm<WT *@  
7. Fas/FasL \P"Ol\@  
9KJ}A i  
8. FcR(ÃâÒßÇòµ°°×Fc¶ÎÊÜÌå) Z.x]6  
LCzeE7x  
9. ϸ°û¼äÕ³¸½·Ö×Ó(ICAM) 9:=:P>  
m],.w M8  
10. Th1/Th2 ,&fZo9J9  
C?W}/r[  
11. »ùÒòÒßÃç(DNAÒßÃç) P*U^,Jh<  
yOAC<<Tzus  
12. chemokines and chemokine receptor f/\S:x- B  
-okq= 9  
13. ÃâÒßÄÍÊÜ a"t~ K  
Zw'050~-  
14. ¹²´Ì¼¤·Ö×Ó vfXNN F  
;+#Nb/M  
15. ËÀÍö½á¹¹Óò(death domain) SXvflr] =m  
%3"U|Za+   
¶þ.ÎÊ´ðÌâ(µÚ1¡¢2Ìâ¸÷18·Ö,µÚ3Ìâ19·Ö) EgbH{)u  
m I:^lp  
1. ÊԱȽÏɱÉËÐÔTϸ°û(CTL)Óë×ÔȻɱÉËϸ°û(NK)ÔÚɱÉË°Ðϸ°û¹ý³ÌÖÐ,ʶ±ðϸ°û¶¾¼°½éµ¼ÃâÒß¹¦ÄÜÓкβ»Í¬? o61rTj  
Q00v(6V46  
2. 70Äê´úÒÔÀ´,ÓйØIgºÍÌåÒºÃâÒßÑо¿´æÔÚÒÔϼ¸ÏîÖØ´ó·¢ÏÖºÍÍ»Æƶø»ñµÃҽѧºÍÉúÎïѧŵ±´¶û½±,Çë·Ö±ð²ûÊöËüÃǵÄÀíÂÛÒâÒå¼°ÔÚҽѧʵ¼ùÖеÄÓ¦ÓᣠnII#uI /!q  
R?2HnJh  
£¨1£©1972Ä꣺θµ°°×øºÍľ¹Ïµ°°×øˮ½âIg£¬»ñµÃFab¡¢Fc¡¢F£¨ab¡¯£©2µÈƬ¶Î )^"V}z t  
y9LO;{(  
£¨2£©1977Ä꣺·ÅÉäÃâÒß·¨ ^Pu:&:ki  
^K_FGE0ec  
£¨3£©1984Ä꣺ÁÜ°Íϸ°ûÔÓ½»ÁöºÍµ¥¿Ë¡¿¹Ìå '=\>n(%Q  
~ F-lO1  
£¨4£©1987Äê: Ig»ùÒòµÄ½á¹¹ 3. ½üÄêÀ´ÔÚÖ×ÁöÃâÒßÑо¿ÁìÓòÖÐÓÐÄÄЩÖØÒª½øÕ¹?ÊÔÊöµ±Ç°Ìá¸ß»úÌ忹Ö×ÁöÃâÒßµÄÖ÷Òª²ßÂÔ¡£ I3'UrKKO  
h+Yd \k  
Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(ÃâÒßѧרҵ) ÎÊ´ðÌâ(ÿÌâ25·Ö) i: jB  
/0fHkj/J=B  
1. ÊԱȽÏTϸ°ûÊÜÌ壨TCR£©¡¢Bϸ°ûÊÜÌ壨BCR£©ºÍNKϸ°ûÊÜÌ壨NKCR£©µÄ×é³É£¬Ê¶±ðÅäÌåÒÔ¼°ÐźÅתµ¼µÄÒìͬµã¡£ !y>up+cRjl  
T}29(xz-(h  
2. ÒÔÐØÏÙÒÀÀµ¿¹Ô­´Ì¼¤»úÌå²úÉú¿¹ÌåµÄÃâÒßÓ¦´ðΪÀý£¬Tϸ°ûºÍBϸ°ûÊÇÈçºÎÏ໥×÷Óã¿ÓÐÄÄЩճ¸½·Ö×Ӻ͹²´Ì¼¤·Ö×Ó²ÎÓëT¡¢Bϸ°ûµÄÏ໥×÷Óã¿ '|) ,?  
 4~ L1~Gk  
3. Éö×ÛºÏÕ÷³öѪÈÈ(HFRS)²¡¶¾µÄ½á¹¹»ùÒòÒѾ­¸ãÇå³þ,ΪÁË֤ʵHFRS²¡¶¾¸ÐȾ»úÌå(ÒÔBalb/CСÊóΪÀý)¿É²úÉúHFRS²¡¶¾ºËÒ¿ǵ°°×(NP)ÌØÒìÐÔCTL,²¢ÔÚÃâÒß·À»¤ÖÐÆðÖØÒª×÷ÓÃ,ÇëÓ¦ÓÃÃâÒßѧÀíÂۺͷ½·¨,Éè¼ÆһϵͳʵÑé,¼ÓÒÔ֤ʵ¡£ 4. Àý¾Ù¶þ¸ö½üÄêÀ´Ï¸°ûºÍ·Ö×ÓÃâÒßѧÑо¿ÖгöÏÖµÄеÄÈȵã,Çë·Ö±ðÆÀÊöÆäÑо¿ÒâÒå¡¢·¢Õ¹Ç÷ÊÆÒÔ¼°Ó¦ÓÃÇ°¾°¡£
ÆÀ¼ÛÒ»ÏÂÄãä¯ÀÀ´ËÌû×ӵĸÐÊÜ

¾«²Ê

¸Ð¶¯

¸ãЦ

¿ªÐÄ

·ßÅ­

ÎÞÁÄ

¹àË®

  
ÃèÊö
¿ìËٻظ´

ÑéÖ¤ÎÊÌâ:
Ãâ·Ñ¿¼²©ÂÛ̳ÍøÖ·ÊÇʲô? ÕýÈ·´ð°¸:freekaobo.com
°´"Ctrl+Enter"Ö±½ÓÌá½»